Syn X, U. of Ottawa, Structural GenomiX, GlaxoSmithKline, Nestle, Ciphergen, Matritech, BioForce | GenomeWeb

Syn X Licenses Patents from U. of Ottawa

Syn X Pharma has exclusively licensed two patents from the University of Ottawa Heart Institute that cover natriuretic peptides in cardiovascular disease. The patents cover inventions by Adolfo de Bold, a professor of pathology and researcher at the UOHI.

De Bold discovered atrial natriuretic factor (ANF), and since October 2000 has been working with Syn X on developing a potential point-of-care test for cardiac diseases based on brain natriuretic peptide, a cardiac hormone related to ANF.

 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.